How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy? - Test2 - elhamkhani - TriplyDB

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

http://www.wikidata.org/entity/Q26744155

about

Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer.

P2860

Q41145348-00BC4870-887F-46D8-990B-D9139692435D

P2860

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

http://www.wikidata.org/entity/Q26744155

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@ast

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@en

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@nl

type

label

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@ast

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@en

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@nl

prefLabel

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@ast

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@en

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@nl

P1433

Q26744155-85BF665B-AA66-4358-AD89-740D8DD5913B

P1476

Q26744155-0D764805-37B5-4372-A0FC-DCE4D06BA6C8

P2093

Q26744155-25B6DBF2-F458-42FF-A636-E7BC73A76ACE

Q26744155-4C0D3D6C-DFB6-428C-82DD-44E83ED140F6

Q26744155-4E9826CC-513C-4812-B553-9C2C99C34AC4

P275

Q26744155-EE32B835-2154-450B-A56B-83FBD6DAB434

P2860

Q26744155-07276303-20DE-40F6-8C53-AE1E240F8F5D

Q26744155-0AD1B21B-5EBC-407F-8E43-C2DC160B6D03

Q26744155-119B138D-0AC5-4250-80C5-D3D37A943DD1

Q26744155-17CF3CAF-624D-4221-BE56-552AEFCBACAA

Q26744155-1A89D0DC-B2A2-41D1-B87F-F11A96CD4768

Q26744155-1DFBBA14-483D-4D95-89B8-5D520A265BAC

Q26744155-2A8F8F86-013A-40C3-8748-EF462C9FF9B2

Q26744155-2B1D9A14-20F6-49FD-9324-42B824C1852C

Q26744155-3829AF12-800A-4637-AC09-8EDD0951FDCB

Q26744155-3E49DAA4-06DB-4AA1-80F6-2302F70CD171

P304

Q26744155-0B2FF39A-23F9-4C91-9AC7-F994F115D710

P31

Q26744155-A98C114B-0E10-4B69-8039-A5456F0181D5

Q26744155-A98EFFC3-E338-48EB-8244-612C243A61DC

P3181

Q26744155-6E2D739A-046E-40EA-9DE8-7AF67AE991CF

P356

Q26744155-095EBC53-797D-4AF4-9F1D-B4B114672C59

P407

Q26744155-400EF6EE-F155-4885-B145-B492DB4BC58A

P433

Q26744155-DA2078D3-1C75-42A9-B8BE-3DDA38F750E5

P478

Q26744155-225596D7-A55B-45BB-A764-ED16340FF5AA

P5008

Q26744155-586B867A-EF89-4AFF-9863-9E5E664CA65F

P577

Q26744155-132E82D9-B9F4-44B6-977C-3AB39D4B0470

P698

Q26744155-3E6E299E-0961-4714-A47C-57E0942DE406

P921

Q26744155-EC01F4BB-15D5-4435-A49F-80FCC09E59F2

P932

Q26744155-87B6B6FF-6509-47C9-82FF-6565840A356D

P3181

P356

ICU.2016.57.S1.S44

P1433

Investigative and clinical urology

P1476

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

@en

P2093

Seok Joong Yun

http://www.w3.org/2001/XMLSchema#string

Seon-Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Wun-Jae Kim

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Incidence of kidney, bladder, and prostate cancers in Korea: An update

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.

Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder

Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.

The value of a second transurethral resection in evaluating patients with bladder tumours.

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study.

Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings

The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer.

P304

S44-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

876335

http://www.w3.org/2001/XMLSchema#string

P356

10.4111/ICU.2016.57.S1.S44

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

57 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27326407

http://www.w3.org/2001/XMLSchema#string

P921

bladder neoplasm

P932

4910762

http://www.w3.org/2001/XMLSchema#string